8-K current report · filed Sep 2, 2026

Parabilis Medicines Inc (PBLS) 8-K Current Report: September 2, 2026

Item 5.02PBLS overview

Short answer

Parabilis Medicines Inc (PBLS) filed an 8-K current report with the SEC on September 2, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Chief Medical Officer Fawzi Benzaghou, M.D. departing effective September 30, 2026.

Parabilis Medicines Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Chief Medical Officer Fawzi Benzaghou, M.D. departing effective September 30, 2026
  • Mutual transition indicates an agreed separation rather than reported involuntary termination
  • Severance payable under Benzaghou’s employment agreement, creating a cash obligation
  • CMO transition may affect clinical development leadership and program execution continuity

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Parabilis Medicines Inc 8-K filings

Get the next PBLS 8-K as it lands

Follow PBLS for push alerts, or ask the research agent what this filing means.